Therapeutic effect of lecithinized superoxide dismutase Against colitis

Tomoaki Ishihara, Ken Ichiro Tanaka, Yuichi Tasaka, Takushi Namba, Jun Suzuki, Tsutomu Ishihara, Susumu Okamoto, Toshifumi Hibi, Mitsuko Takenaga, Rie Igarashi, Keizo Sato, Yutaka Mizushima, Tohru Mizushima

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Ulcerative colitis (UC) involves intestinal mucosal damage induced by reactive oxygen species (ROS), in particular, super-oxide anion. Superoxide dismutase (SOD) catalyzes dismutation of superoxide anion to hydrogen peroxide, which is subsequently detoxified by catalase. Lecithinized SOD (PC-SOD) is a new modified form of SOD that has overcome previous clinical limitations of SOD. In this study, we examined the action of PC-SOD using an animal model of UC, dextran sulfate sodium (DSS)-induced colitis. DSS-induced colitis was amelio rated by daily intravenous administration of PC-SOD. Unmodified sOd produced a similar effect but only at more than 30 times the concentration of PC-SOD. In vivo electron spin resonance analysis confirmed that the increase in the colonic level of ROS associated with development of colitis was suppressed by PC-SOD administration. The dose-response profile of PC-SOD was bell-shaped, but simultaneous administration of catalase restored the ameliorative effect at high doses of PC-SOD. Accumulation of hydrogen peroxide was observed with the administration of high doses of PC-SOD, an effect that was suppressed by the simultaneous administration of catalase. We also found that either a weekly intravenous administration or daily oral administration of PC-SOD conferred protection. These results suggest that PC-SOD achieves its ameliorative effect against colitis through decreasing the colonic level of ROS and that its ineffectiveness at higher doses is because of the accumulation of hydrogen peroxide. Furthermore, we consider that intermittent or oral administration of PC-SOD can be applied clinically to improve the quality of life of UC patients.

Original languageEnglish
Pages (from-to)152-164
Number of pages13
JournalJournal of Pharmacology and Experimental Therapeutics
Volume328
Issue number1
DOIs
Publication statusPublished - 2009 Jan
Externally publishedYes

Fingerprint

Therapeutic Uses
Colitis
Superoxide Dismutase
Ulcerative Colitis
Catalase
Hydrogen Peroxide
Reactive Oxygen Species
Dextran Sulfate
lecithinized superoxide dismutase
Intravenous Administration
Oral Administration
Electron Spin Resonance Spectroscopy
Superoxides
Oxides
Anions
Animal Models

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Medicine(all)

Cite this

Ishihara, T., Tanaka, K. I., Tasaka, Y., Namba, T., Suzuki, J., Ishihara, T., ... Mizushima, T. (2009). Therapeutic effect of lecithinized superoxide dismutase Against colitis. Journal of Pharmacology and Experimental Therapeutics, 328(1), 152-164. https://doi.org/10.1124/jpet.108.144451

Therapeutic effect of lecithinized superoxide dismutase Against colitis. / Ishihara, Tomoaki; Tanaka, Ken Ichiro; Tasaka, Yuichi; Namba, Takushi; Suzuki, Jun; Ishihara, Tsutomu; Okamoto, Susumu; Hibi, Toshifumi; Takenaga, Mitsuko; Igarashi, Rie; Sato, Keizo; Mizushima, Yutaka; Mizushima, Tohru.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 328, No. 1, 01.2009, p. 152-164.

Research output: Contribution to journalArticle

Ishihara, T, Tanaka, KI, Tasaka, Y, Namba, T, Suzuki, J, Ishihara, T, Okamoto, S, Hibi, T, Takenaga, M, Igarashi, R, Sato, K, Mizushima, Y & Mizushima, T 2009, 'Therapeutic effect of lecithinized superoxide dismutase Against colitis', Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 1, pp. 152-164. https://doi.org/10.1124/jpet.108.144451
Ishihara, Tomoaki ; Tanaka, Ken Ichiro ; Tasaka, Yuichi ; Namba, Takushi ; Suzuki, Jun ; Ishihara, Tsutomu ; Okamoto, Susumu ; Hibi, Toshifumi ; Takenaga, Mitsuko ; Igarashi, Rie ; Sato, Keizo ; Mizushima, Yutaka ; Mizushima, Tohru. / Therapeutic effect of lecithinized superoxide dismutase Against colitis. In: Journal of Pharmacology and Experimental Therapeutics. 2009 ; Vol. 328, No. 1. pp. 152-164.
@article{c1f18cb272194a56a07b528701449cd0,
title = "Therapeutic effect of lecithinized superoxide dismutase Against colitis",
abstract = "Ulcerative colitis (UC) involves intestinal mucosal damage induced by reactive oxygen species (ROS), in particular, super-oxide anion. Superoxide dismutase (SOD) catalyzes dismutation of superoxide anion to hydrogen peroxide, which is subsequently detoxified by catalase. Lecithinized SOD (PC-SOD) is a new modified form of SOD that has overcome previous clinical limitations of SOD. In this study, we examined the action of PC-SOD using an animal model of UC, dextran sulfate sodium (DSS)-induced colitis. DSS-induced colitis was amelio rated by daily intravenous administration of PC-SOD. Unmodified sOd produced a similar effect but only at more than 30 times the concentration of PC-SOD. In vivo electron spin resonance analysis confirmed that the increase in the colonic level of ROS associated with development of colitis was suppressed by PC-SOD administration. The dose-response profile of PC-SOD was bell-shaped, but simultaneous administration of catalase restored the ameliorative effect at high doses of PC-SOD. Accumulation of hydrogen peroxide was observed with the administration of high doses of PC-SOD, an effect that was suppressed by the simultaneous administration of catalase. We also found that either a weekly intravenous administration or daily oral administration of PC-SOD conferred protection. These results suggest that PC-SOD achieves its ameliorative effect against colitis through decreasing the colonic level of ROS and that its ineffectiveness at higher doses is because of the accumulation of hydrogen peroxide. Furthermore, we consider that intermittent or oral administration of PC-SOD can be applied clinically to improve the quality of life of UC patients.",
author = "Tomoaki Ishihara and Tanaka, {Ken Ichiro} and Yuichi Tasaka and Takushi Namba and Jun Suzuki and Tsutomu Ishihara and Susumu Okamoto and Toshifumi Hibi and Mitsuko Takenaga and Rie Igarashi and Keizo Sato and Yutaka Mizushima and Tohru Mizushima",
year = "2009",
month = "1",
doi = "10.1124/jpet.108.144451",
language = "English",
volume = "328",
pages = "152--164",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Therapeutic effect of lecithinized superoxide dismutase Against colitis

AU - Ishihara, Tomoaki

AU - Tanaka, Ken Ichiro

AU - Tasaka, Yuichi

AU - Namba, Takushi

AU - Suzuki, Jun

AU - Ishihara, Tsutomu

AU - Okamoto, Susumu

AU - Hibi, Toshifumi

AU - Takenaga, Mitsuko

AU - Igarashi, Rie

AU - Sato, Keizo

AU - Mizushima, Yutaka

AU - Mizushima, Tohru

PY - 2009/1

Y1 - 2009/1

N2 - Ulcerative colitis (UC) involves intestinal mucosal damage induced by reactive oxygen species (ROS), in particular, super-oxide anion. Superoxide dismutase (SOD) catalyzes dismutation of superoxide anion to hydrogen peroxide, which is subsequently detoxified by catalase. Lecithinized SOD (PC-SOD) is a new modified form of SOD that has overcome previous clinical limitations of SOD. In this study, we examined the action of PC-SOD using an animal model of UC, dextran sulfate sodium (DSS)-induced colitis. DSS-induced colitis was amelio rated by daily intravenous administration of PC-SOD. Unmodified sOd produced a similar effect but only at more than 30 times the concentration of PC-SOD. In vivo electron spin resonance analysis confirmed that the increase in the colonic level of ROS associated with development of colitis was suppressed by PC-SOD administration. The dose-response profile of PC-SOD was bell-shaped, but simultaneous administration of catalase restored the ameliorative effect at high doses of PC-SOD. Accumulation of hydrogen peroxide was observed with the administration of high doses of PC-SOD, an effect that was suppressed by the simultaneous administration of catalase. We also found that either a weekly intravenous administration or daily oral administration of PC-SOD conferred protection. These results suggest that PC-SOD achieves its ameliorative effect against colitis through decreasing the colonic level of ROS and that its ineffectiveness at higher doses is because of the accumulation of hydrogen peroxide. Furthermore, we consider that intermittent or oral administration of PC-SOD can be applied clinically to improve the quality of life of UC patients.

AB - Ulcerative colitis (UC) involves intestinal mucosal damage induced by reactive oxygen species (ROS), in particular, super-oxide anion. Superoxide dismutase (SOD) catalyzes dismutation of superoxide anion to hydrogen peroxide, which is subsequently detoxified by catalase. Lecithinized SOD (PC-SOD) is a new modified form of SOD that has overcome previous clinical limitations of SOD. In this study, we examined the action of PC-SOD using an animal model of UC, dextran sulfate sodium (DSS)-induced colitis. DSS-induced colitis was amelio rated by daily intravenous administration of PC-SOD. Unmodified sOd produced a similar effect but only at more than 30 times the concentration of PC-SOD. In vivo electron spin resonance analysis confirmed that the increase in the colonic level of ROS associated with development of colitis was suppressed by PC-SOD administration. The dose-response profile of PC-SOD was bell-shaped, but simultaneous administration of catalase restored the ameliorative effect at high doses of PC-SOD. Accumulation of hydrogen peroxide was observed with the administration of high doses of PC-SOD, an effect that was suppressed by the simultaneous administration of catalase. We also found that either a weekly intravenous administration or daily oral administration of PC-SOD conferred protection. These results suggest that PC-SOD achieves its ameliorative effect against colitis through decreasing the colonic level of ROS and that its ineffectiveness at higher doses is because of the accumulation of hydrogen peroxide. Furthermore, we consider that intermittent or oral administration of PC-SOD can be applied clinically to improve the quality of life of UC patients.

UR - http://www.scopus.com/inward/record.url?scp=59149097248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149097248&partnerID=8YFLogxK

U2 - 10.1124/jpet.108.144451

DO - 10.1124/jpet.108.144451

M3 - Article

C2 - 18927353

AN - SCOPUS:59149097248

VL - 328

SP - 152

EP - 164

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -